title: A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
abstract: Previous studies indicate that BRCA1 protein binds to estrogen receptor-alpha (ER) and inhibits its activity. Here, we found that BRCA1 over-expression not only inhibits ER activity in anti-estrogen-resistant LCC9 cells but also partially restores their sensitivity to Tamoxifen. To simulate the mechanism of BRCA1 inhibition of ER in the setting of Tamoxifen resistance, we created a three-dimensional model of a BRCA1-binding cavity within the ER/Tamoxifen complex; and we screened a pharmacophore database to identify small molecules that could fit into this cavity. Among the top 40 "hits", six exhibited potent ER inhibitory activity in anti-estrogen-sensitive MCF-7 cells and four of the six exhibited similar activity (IC50 ≤ 1.0 μM) in LCC9 cells. We validated the model by mutation analysis. Two representative compounds (4631-P/1 and 35466-L/1) inhibited ER-dependent cell proliferation in Tamoxifen-resistant cells (LCC9 and LCC2) and partially restored sensitivity to Tamoxifen. The compounds also disrupted the association of BRCA1 with ER. In electrophoretic mobility shift assays, the compounds caused dissociation of ER from a model estrogen response element. Finally, a modified form of compound 35446 (hydrochloride salt) inhibited growth of LCC9 tumor xenografts at non-toxic concentrations. These results identify a novel group of small molecules that can overcome Tamoxifen resistance.
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Yongxian
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Anju
authors.initials: A
authors.lastname: Preet
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Center for Drug Discovery, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: York
authors.initials: Y
authors.lastname: Tomita
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Center for Drug Discovery, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Eliseu
authors.initials: E
authors.lastname: De Oliveira
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Center for Drug Discovery, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Ueda
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Clarke
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Center for Drug Discovery, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Milton
authors.initials: M
authors.lastname: Brown
authors.affiliation: Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Biochemistry and Molecular and Cellular Biology, Georgetown University School of Medicine, Washington, DC, USA.|Department of Radiation Medicine, Georgetown University School of Medicine, Washington, DC, USA.
authors.forename: Eliot M
authors.initials: EM
authors.lastname: Rosen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D019313:BRCA1 Protein / Q000037:antagonists & inhibitors*; D001577:Benzophenones / Q000737:chemistry / Q000494:pharmacology*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D047188:Chalcones / Q000737:chemistry / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D024202:Electrophoretic Mobility Shift Assay; D004965:Estrogen Antagonists / Q000737:chemistry* / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors*; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D047468:Immunoprecipitation; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D054852:Small Molecule Libraries / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: C000611208:1,3-diphenyl-3-(piperidin-1-yl)propan-1-one; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D001577:Benzophenones; D047188:Chalcones; C506487:ESR1 protein, human; D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D004967:Estrogens; C000611207:NSC 4631; D010880:Piperidines; D054852:Small Molecule Libraries; D013629:Tamoxifen
keywords: BRCA1; Tamoxifen; agonist; antagonist; estrogen receptor (ER-α)